Aripiprazole monotherapy in an adolescent worsens psychosis

Panigrahi, Mahima; Padhy, Susanta Kumar; Rathi, Rajesh
March 2013
Indian Journal of Pharmacology;Mar/Apr2013, Vol. 45 Issue 2, p195
Academic Journal
Early detection and treatment of early onset schizophrenia (EOS) can lead to better outcome. Aripiprazole, a partial agonist of dopamine and a second generation antipsychotic, has been approved specifically for treatment of children with schizophrenia of aged 13-17 years. Though the use of this drug in adults may be associated with worsening of psychosis in occasional cases, no such data is available in adolescents. We report a case of EOS, who had worsening of psychosis with aripiprazole monotherapy. We discuss the possible mechanisms and clinical implications relevant in adolescents, and alert the clinicians to be vigilant in monitoring the patients on aripiprazole, especially after an increase in the dose of this medication.


Related Articles

  • Caution urged with atypical antipsychotics.  // Medical Journal of Australia;12/3/2012, Vol. 197 Issue 11/12, p605 

    The article warns that commonly prescribed atypical antipsychotics (AAPs), including aripiprazole, olanzapine and quetiapine, lack effectiveness and have a high incidence of adverse effects in middle-aged and older patients with psychotic disorders according to U.S. research.

  • Partial Dopamine Agonists and the Treatment of Psychosis. Tamminga, Carol A. // Current Neuropharmacology;Jan2005, Vol. 3 Issue 1, p3 

    Pharmacologic approaches that diminish dopamine-mediated neural transmission in brain have antipsychotic actions in humans. Blockade of D2 family dopamine receptors is the most common strategy. A paradoxical strategy of using dopamine agonists in particular circumstances to similarly diminish...

  • Antipsychotics in Adults With Schizophrenia: Comparative Effectiveness of First-Generation Versus Second-Generation Medications. Hartling, Lisa; Abou-Setta, Ahmed M.; Dursun, Serdar; Mousavi, Shima S.; Pasichnyk, Dion; Newton, Amanda S. // Annals of Internal Medicine;10/2/2012, Vol. 157 Issue 7, p498 

    Background: Debate continues about the comparative benefits and harms of first-generation antipsychotics (FCAs) and second-generation antipsychotics (SGAs) in treating schizophrenia. Purpose: To compare the effects of FGAs with those of SGAs in the treatment of adults aged 18 to 64 years with...

  • Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). Kelly, Deanna L.; Wehring, Heidi J.; Earl, Amber K.; Sullivan, Kelli M.; Dickerson, Faith B.; Feldman, Stephanie; McMahon, Robert P.; Buchanan, Robert W.; Warfel, Dale; Keller, William R.; Fischer, Bernard A.; Joo-Cheol Shim // BMC Psychiatry;2013, Vol. 13 Issue 1, p1 

    Prolactin elevations occur in people treated with antipsychotic medications and are often much higher in women than in men. Hyperprolactinemia is known to cause amenorrhea, oligomenorrhea, galactorrhea and gynecomastia in females and is also associated with sexual dysfunction and bone loss....

  • Aripiprazole.  // AHFS Consumer Medication Information;Sep2020, p1 

    Aripiprazole is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions) in adults and teenagers 13 years of age and older. It is also used alone or with other medications to treat...

  • Paliperidone: the evidence of its therapeutic value in schizophrenia. Kantrowitz, Joshua; Citrome, Leslie // Core Evidence;2008, Vol. 2 Issue 4, p261 

    Introduction: Paliperidone, the 9-hydroxy metabolite of risperidone, is a second-generation antipsychotic that was recently approved for the treatment of schizophrenia. It is marketed as an improvement over risperidone, but is likely to be considerably more costly when risperidone is no longer...

  • olanzapine.  // Taber's Cyclopedic Medical Dictionary;2005, p1514 

    A definition of the term "olanzapine" is presented. It refers to an atypical antipsychotic agent used to treat psychosis and schizophrenia. Olanzapine controls both the positive and negative symptoms of schizophrenia. Extrapyramidal side effects are less commonly linked with the use of...

  • Is cabergoline a better drug to inhibit lactation in patients with psychotic symptoms? Pertegaz, Immaculada Baeza; alberdi, Jose Manuel Goikolea; Rodon, Eduard Parellada // Journal of Psychiatry & Neuroscience;Jan2002, Vol. 27 Issue 1, p54 

    Evaluates the use of the dopamine agonist, cabergoline, to inhibit lactation in patients with psychotic symptoms. Higher specificity and affinity for the dopamine D[sub 2] receptor and longer lasting suppression of prolactin release of the compound than bromocriptine; Adverse effects of the...

  • The Effect of Aripiprazole on Psychosis in the Presence of a Dopamine Agonist. Casey, Meaghan; Greenspan, Heather; Shiva, Suparna; Zandnia, Shahrooz // Psychiatric Annals;Feb2013, Vol. 43 Issue 2, p52 

    The article describes the case of a 48-year-old woman with a history of anxiety disorder and presented with late-onset psychosis. She was given aripiprazole for psychosis. The dopamine agonist cabergoline was later prescribed for her pituitary tumor. Results of the patient's complete blood count...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics